Portfolio
-
The ELIOS™ procedure offers an implant-free, minimally invasive glaucoma surgery (MIGS) option that creates precise microscopic channels inside the eye that may increase the flow of fluid and lower eye pressure.
Publication:
-
Developing next generation long acting biodegradable drug delivery platform.
News:
Re-Vana Therapeutics Raises $3.25 Million in Pre-Series A Financing
Dr. Rahhal Interview Re-Vana Therapeutics, Ltd. CEO Michael O'Rourke
-
A biomimetic accommodating intraocular lens
News:
OIS Podcast – Ram Rao, CEO LensGen
LensGen® Closes $10 Million Financing and Welcomes James V. Mazzo to its Board of Directors
Publication:
Long-term biocompatibility of a new fluid-filled, modular accommodating IOL
-
Enabling delivery of precision RNA therapeutics
News:
Completes $100M Series B to Advance its FALCON™ Platform and RNA Therapeutics
Publication:
Biocentury | DTx: Optimizing RNA therapies for cellular uptake, biodistribution
-
Developing novel compounds to treat corneal dystrophies
News:
Restoring vision loss with a regenerative therapy
Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial
Publications:
A Bell-Shaped Dose Response of Topical FGF-1 in Dermal Wound Healing
-
Revolutionizing the eye exam
News:
Envision Diagnostics raises Series A Financing
Publication:
Automated Pupillometry Using a Prototype Binocular OCT System
-
Quantum Dots to treat retinal disease
Studies:
Library
-
Pioneering an entirely new approach to preserving sight
News:
ONL Therapeutics Closes $46.9 Million in Series B
ONL Therapeutics featured on the OIS Retina Podcast with Dr. Rahhal
ONL Therapeutics Announces First Patient Treated in Phase I Study With ONL1204
-
(Acquired: Allergan)
First-in-class optogenetic therapy to treat retinal diseasesNews:
Allergan Acquires Gene Therapy Company RetroSense Therapeutics
-
Valitor is conquering the limitations of established drug targets by leveraging its multi-valent biopolymer to engineer disruptive medicines.
-
Novai is a disruptive British biotech start-up with an AI-supported retinal biomarker for use in glaucoma and AMD clinical trials.